Navigation Links
iBio Adds New Therapeutic Antibody to Its Pipeline
Date:3/4/2013

eins difficult or impossible to produce with other methods; broad applicability to biologics, including therapeutic proteins and vaccines; production time measured in weeks instead of months or more. Additional benefits may include a surge capacity for remedial action against bioterrorism and pandemic disease including influenza; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production.

About Influenza

Influenza virus infection is a common infectious disease that often causes mild symptoms but can lead to severe symptoms and death. Influenza epidemics occur yearly, causing three to five million cases of severe illness, and about 250,000 to 500,000 deaths worldwide. Although the common strains of influenza constitute a significant public health concern, more dangerous influenza strains have emerged periodically leading to pandemics that kill millions of people. The high mutation rate of influenza viruses leads to the frequent emergence of new strains and also to the development of resistance to antiviral drugs. An effective antibody-based influenza drug based on iBio technology has the potential to effectively treat such drug-resistant infections as well as complex and advanced infections.

About Antibody Therapeutics

The use of monoclonal antibodies for the treatment of a wide variety of diseases and illnesses has emerged as one of the most important contributions of biotechnology to clinical medicine. A few dozen antibody products generate global annual sales of about $50 billion, and several hundred new product candidates are in clinical trials for many medical applications. Rituximab is an antibody drug approved for treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other diseases, generating annual sales in excess of $6 billion. Palivizumab is an antibody drug used to prevent serious lung infections caused
'/>"/>

SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
2. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
3. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. United Therapeutics Announces Additional $420 Million Share Repurchase Program
6. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
7. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
8. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
9. Shield Therapeutics Selects OpenClinica Enterprise
10. Regenetek Research Inc. Launches New Intelligent Software for Therapeutic Stem Cell Trials
11. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Senomyx , Inc. (NASDAQ: ... to discover, develop, and commercialize novel flavor ingredients, announced ... the Company,s Vice President, Biology and Gwen ... Communications, will present an overview of Senomyx,s technology and ... Time (7:25 a.m. Pacific Time) during the Citi 2013 ...
(Date:5/24/2013)... 24, 2013 Many factors impact tissues ... or efflux transporters at the blood-tissue barrier. Even when ... unbound fractions in the tissue rather than the total ... challenges is required to guide lead optimization, predict in ... species-dependent variables that may impact the likely human clinical ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly ... and development, sales and marketing of premium branded ... that it is awarding exclusive Vestiage territories in ... Skin Illuminating Facial Care. Qualified applicants can request ... email to info(at)vestiageinc(dot)com and putting RELUMA in the ...
(Date:5/23/2013)... CAMBRIDGE, England , May 24, 2013 ... von Mundipharma angefertigt – Bei der ... Version , 91 % der Teilnehmer einer ... obwohl nur 20 % laut GINA [*] -Definition [1] ... zeigt, dass Menschen mit Asthma generell einer von vier ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... Ohio, June 22, 2011 With the intent to ... disease in Akron, the Austen BioInnovation Institute in Akron ... the conference "Healthier by Design: Creating Accountable Care Communities" ... regional health and wellness thought-leaders, the strategic discussion is ...
... Colorado Institute for Drug, Device and Diagnostic Development ... the Colorado life science ecosystem through company creation ... Veterinary Emerging Technologies Development Corporation (VetDC) to receive ... commercializes technologies to address serious unmet medical needs ...
... 2011 VENENUM Biodesign, a drug discovery company that ... to identify potential therapeutic agents against its novel disease-based ... opened its new medicinal chemistry space at 8 Black ... facility comprises over 11,000 square feet of state-of-the-art research ...
Cached Biology Technology:Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 2Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 3Colorado Institute for Drug, Device and Diagnostic Development Awards Funding to Fort Collins-based VetDC 2VENENUM Biodesign Announces Opening of Medicinal Chemistry Labs 2
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
(Date:5/23/2013)... when microbial pathogens are growing increasingly resistant to the ... of Wisconsin scientists has synthesized a potent new class ... staph infections. , Writing online in the Journal ... by University of Wisconsin-Madison chemistry Professor Helen Blackwell describes ... of Staphylococcus aureus , a bacterium at the ...
(Date:5/22/2013)... investigators also conclude that the 20 percent reduction ... (LDCT) versus chest X-ray (CXR) screening previously reported ... experienced screening centers in the United States. , ... their patients about the benefits and risks of ... the New England Journal of Medicine ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... An ichthyologist from the Wildlife Conservation Society's New York ... fish discovered on the African island nation of Madagascar ... has dedicated much of his career safeguarding Madagascar's little- ... of biologists from the American Museum of Natural History ...
... discovered to their surprise that a drug commonly used ... growth of new blood vessels commonly seen in cancers. ... use, which may fast-track its availability as an antiangiogenesis ... blood vessel growth, treatment with itraconazole reduced blood vessel ...
... As more and more corn grain is diverted to ... shortages. However, ethanol made from cellulosic materials instead of ... according to research by a Michigan State University ethanol ... materials science professor, has used life cycle analysis tools, ...
Cached Biology News:Anti-fungal drug stops blood vessel growth 2With cellulosic ethanol, there is no food vs. fuel debate according to MSU scientist 2
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Request Info...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
... Maker, 1. Modular system for large ... up to six lab-cast or precast ... with 18- or 24-cm Immobiline DryStrip ... gel cassettes.Innovative design simplifies loading and ...
Biology Products: